Model of CE of dexamethasone for Covid-19_24Aug20.xlsx (1022.92 kB)
MOSAIC: A model to assess the cost-effectiveness of dexamethasone for admitted COVID-19 patients in South Africa
Version 4 2020-09-14, 14:23
Version 3 2020-07-23, 07:20
Version 2 2020-07-13, 10:22
Version 1 2020-06-26, 11:01
dataset
posted on 2020-09-14, 14:23 authored by Susan ClearySusan Cleary, Cynthia Tamandjou TchuemCynthia Tamandjou Tchuem, geetesh solankigeetesh solanki, Sumaiyah DocratSumaiyah Docrat, Donela BesadaDonela Besada, Tommy WilkinsonTommy Wilkinson| MODEL STRATEGIES |
| This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death. |
Two competing strategies are modelled: |
| 1. The "status quo" summarizes costs and outcomes for patients assuming usual care (no dexamethasone). |
| 2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming usual care with dexamethasone at 6mg/day over 10 days. |
| |
| MODEL OUTCOMES |
| Cost: mean cost (general ward and ICU) per admitted patient from the health care provider's perspective. |
| Health outcomes: mean DALYs and deaths per admitted patient. |
| Other: mean ICU days and inpatient days per admitted patient. |
